World P2X Purinoceptor 3 (P2RX3) Therapeutics Pipeline Review 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2016" report to their offering.

'P2X Purinoceptor 3 - Pipeline Review, H1 2016'; P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities

Institutes.

Furthermore, the publisher says; P2X Purinoceptor 3 (P2RX3) P2X purinoceptor 3 is a protein that in humans is encoded by the P2RX3 gene. It belongs to the family of purinoceptors for ATP. This receptor functions as a ligand-gated ion channel and may transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes.

The report 'P2X Purinoceptor 3 - Pipeline Review, H1 2016' outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. P2X Purinoceptor 3 Overview
  3. Therapeutics Development
  4. Pipeline Products for P2X Purinoceptor 3 - Overview
  5. Pipeline Products for P2X Purinoceptor 3 - Comparative Analysis
  6. P2X Purinoceptor 3 - Therapeutics under Development by Companies
  7. P2X Purinoceptor 3 - Therapeutics under Investigation by Universities/Institutes
  8. P2X Purinoceptor 3 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. P2X Purinoceptor 3 - Products under Development by Companies
  13. P2X Purinoceptor 3 - Products under Investigation by Universities/Institutes
  14. P2X Purinoceptor 3 - Companies Involved in Therapeutics Development
  • Afferent Pharmaceuticals, Inc.
  • Asana BioSciences, LLC
  • Integral Molecular, Inc.
  • Neurim Pharmaceuticals Ltd
  • Pfizer Inc.
  • Shionogi & Co., Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/rnjdgk/p2x_purinoceptor

Related Topics: Central Nervous System Drugs, Liver and Kidney Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716